Gaudium IVF and Women Health Limited IPO
Healthcare Service Provider · DRHP 21 Jan 2025 · listed 27 Feb 2026
Follow this IPOuse-of-proceeds reports, on Telegram
- Issue price
- ₹79.00
- band ₹75.00 to ₹79.00
- Issue size
- ₹75.0 cr
- fresh - · OFS ₹75 cr
- Lot
- 189 shares
- ₹14,931 at the top of the band
- Subscription window
- 20 Feb to 24 Feb
- 2026
- Listing
- 27 Feb 2026
- NSE
- Subscribed
- 5.7x
- retail 5.9x
About the Gaudium IVF and Women Health IPO
Gaudium IVF and Women Health Limited raised ₹75 crore through a mainboard IPO on NSE and BSE: an offer for sale of ₹75 crore.
Bidding ran Fri 20 Feb to Tue 24 Feb, at an issue price of ₹79 a share, in lots of 189 shares. The shares listed on 27 Feb 2026.
The book-running lead manager is Sarthi Capital Advisors Private Limited. The registrar, which handles allotment, is Bigshare Services Private Limited.
The issue was subscribed 5.66 times overall, with the retail portion at 5.88 times, as the exchange's bid book showed.
The draft offer document was filed on 21 Jan 2025.
newboard writes its studies from the offer document before an issue lists, and this one listed without one. The figures on this page are the exchange's and the offer document's, each with its source.
Gaudium IVF and Women Health IPO: questions answered
When was the Gaudium IVF and Women Health IPO open, and what were the price band and lot size?
Bidding ran Fri 20 Feb to Tue 24 Feb. The issue price is ₹79 a share. One lot is 189 shares, ₹14,931 at the upper end of the band.
When did the Gaudium IVF and Women Health IPO list?
The shares listed on 27 Feb 2026 on NSE and BSE.
How do I check the Gaudium IVF and Women Health IPO allotment status?
Allotment is finalised by the registrar, Bigshare Services Private Limited, usually the working day after the issue closes. Check it on the registrar's website or on BSE and NSE with a PAN, application number or DP ID. Shares not allotted have their blocked amount released by the refund date.
The Gaudium IVF and Women Health IPO allotment status page, with the direct links
Who are the registrar and lead managers of the Gaudium IVF and Women Health IPO?
The book-running lead manager is Sarthi Capital Advisors Private Limited. The registrar, which handles applications and allotment, is Bigshare Services Private Limited.
How many times was the Gaudium IVF and Women Health IPO subscribed?
5.66 times overall, as the exchange's bid book last showed: qualified institutions 0.93 times, non-institutional investors 12.83 times and retail 5.88 times.
Is the Gaudium IVF and Women Health IPO a fresh issue or an offer for sale?
It includes an offer for sale of ₹75 crore: that money goes to the shareholders selling, not to the company.
What is the Gaudium IVF and Women Health IPO GMP?
newboard does not publish a grey-market premium. Grey-market deals happen outside the stock exchanges, are not regulated, and leave no public record of who traded at what price. What is on record is the offer document, read on this page, and the exchanges' bid book.
Where the money went
The monitoring agency's report for the quarter to 30 Jun 2026: each object in the offer document and how much of it had been used by then.
| Object | Proposed, ₹ crore | Used, ₹ crore |
|---|---|---|
| Funding capital expenditure towards establishme nt of New IVF Centres of the Company | 50.0 | 1.0 |
| General Corporate Purpose | 12.3 | 1.0 |
| Issue Expenses | 7.7 | 7.7 |
| Repayment or pre- payment, in full or part, of certain borrowings availed by our Company | 20.0 | 18.1 |
| TOTAL | 90.0 | 25.3 |
Gaudium IVF and Women Health IPO: the next step, on Telegram
A message when there is news on each use-of-proceeds report the company files. Free, no account, leave in one tap. Send /stop to end it.
Not on this page yet: an offer-document study, the peer table the issuer printed. Each is added when the pipeline extracts it from the offer document.
The figures on this page are the company's own, taken from its filings with the exchanges and SEBI, and every number links to the document and page it came from. They are reproduced as stated, not verified independently, and they are not forecasts by newboard.in. Nothing here is investment advice, a research report or a recommendation. newboard.in is not a SEBI-registered research analyst or investment adviser.